Nemucore Medical Innovations, Inc.

Wellesley, MA 02481

SBIR Award Summary

Total Number of Awards 5
Total Value of Awards $1.04MM
First Award Date 09/21/10
Most Recent Award Date 02/01/15

Key Personnel

Last Name Name Awards Contact
Coleman Timothy Patrick Coleman 5
Ganta Srinivas Ganta 1

5 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 02/01/15 - 01/31/16

DESCRIPTION (provided by applicant): Ovarian cancer is a highly lethal gynecologic cancer with an estimated 21,860 new cases and approximately 13,850 deaths in the USA per year. In a large majority of the patients, cancer reoccurs after initial treatment and manifest resistance to conventional and novel chemotherapeutic agents, thereby represent...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-234
Budget: 08/01/14 - 07/31/15

DESCRIPTION (provided by applicant): Ovarian cancer is a highly lethal gynecologic cancer with an estimated 21,860 new cases and approximately 13,850 deaths in the USA per year. A large majority of the patients, cancer reoccurs after initial treatment and manifest resistance to conventional and novel chemotherapeutic agents representing a form...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PAR-10-286
Budget: 04/26/13 - 03/31/14

DESCRIPTION (provided by applicant): PROJECT SUMMARY This proposal is a Phase 1 proposal in response to The National Institute of Health Small Business Innovation Research (SBIR) Program call for proposals for the Cancer Diagnostics and Therapeutic Agents Enabled By Nanotechnology (SBIR [U43/U44]) [Program Announcement Number: PA-10-286]. Nemuc...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-042
Budget: 09/06/11 - 08/31/12

DESCRIPTION (provided by applicant): Today 70% of patients with advanced ovarian cancer will achieve clinically complete remission with front line treatments of carboplatin and paclitaxel, unfortunately a majority these patients are destined to relapse and eventually die of disease within 12-18 months due to a persistence of chemoresistant cells...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-042
Budget: 09/21/10 - 08/31/11

DESCRIPTION (provided by applicant): Today 70% of patients with advanced ovarian cancer will achieve clinically complete remission with front line treatments of carboplatin and paclitaxel, unfortunately a majority these patients are destined to relapse and eventually die of disease within 12-18 months due to a persistence of chemoresistant cells...